The mitochondrial permeability transition pore as a target for cardioprotection in hypertrophic cardiomyopathy

Cardiovascular Drugs and Therapy

Volumn 27, Issue 3, 2013, Pages 235-237

  Rees, P S C ^a,d   Davidson, S M ^a   Harding, S E ^b   McGregor, C ^c   Elliot, P M ^c   Yellon, D M ^a   Hausenloy, D J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Atorvastatin; Ciclosporin A; Hypertrophic cardiomyopathy; MPTP; Myocardial ischemia reperfusion injury

Indexed keywords

ATORVASTATIN; CYCLOSPORIN A; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; CARDIOTONIC AGENT; CARRIER PROTEIN; CYCLOSPORIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CORONARY ARTERY BYPASS GRAFT; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; CELL CULTURE; CHANNEL GATING; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG EFFECT; HEART MITOCHONDRION; HEART MUSCLE CELL; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; REPERFUSION INJURY; TIME;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTONIC AGENTS; CELLS, CULTURED; CYCLOSPORINE; HEPTANOIC ACIDS; HUMANS; ION CHANNEL GATING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PYRROLES; TIME FACTORS;

EID: 84887357985     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6447-z     Document Type: Article

References (9)

1. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866-75.
2. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role inmediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 2003;35(4):339-41.
3. Leung AW, Halestrap AP. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta. 2008;1777(7-8):946-52.
4. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 2003;60 (3):617-25.
5. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM. Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol. 2005;289 (1):H237-42.
6. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359 (5):473-81.
7. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38(2):367- 74.
8. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther. 2009;122(1):30-43.
9. Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006;290(5):H1960-8.